New treatment options in the management of IBD – focus on colony stimulating factors
Josué Barahona-Garrido, Jesús K Yamamoto-FurushoInflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Mexico City...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ae4eb40bcbdc485595374bc0943d78f7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ae4eb40bcbdc485595374bc0943d78f7 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ae4eb40bcbdc485595374bc0943d78f72021-12-02T01:46:10ZNew treatment options in the management of IBD – focus on colony stimulating factors1177-54751177-5491https://doaj.org/article/ae4eb40bcbdc485595374bc0943d78f72008-09-01T00:00:00Zhttp://www.dovepress.com/new-treatment-options-in-the-management-of-ibd-ndash-focus-on-colony-s-a2299https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Josué Barahona-Garrido, Jesús K Yamamoto-FurushoInflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Mexico City, MexicoAbstract: Inflammatory bowel disease (IBD) is characterized by inflammation of the gastrointestinal tract, typically with a relapsing and remitting clinical course. The intestinal inflammation in IBD is controlled by a complex interplay of innate and adaptive immune mechanisms. Innate immunity comprises a set of distinct elements, which includes circulating cells such as neutrophils, monocytes, and resident intestinal immune cells (dendritic and Paneth cells), as well as intestinal epithelium and cellular products, including antimicrobial peptides such as defensins and cathelicidins. Different components of innate immunity in IBD have been suggested to be defective or impaired. The human granulocyte-macrophage colony-stimulating factor (GM-CSF) and the human granulocyte colony-stimulating factor (G-CSF) have emerged as potential tools for the modulation of intestinal inflammation and repair. The greatest evidence supporting the use of colony-stimulating factors in intestinal inflammation comes from studies conducted in active Crohn’s disease (CD) patients treated with sargramostim and filgrastim, but evidence for its recommendation as treatment remains weak, as the majority of studies are open label, nonrandomized, and with a small number of patients.Keywords: inflammatory bowel disease, colony stimulating factors, sargramostim, filgrastim Josué Barahona-GarridoJesús K Yamamoto-FurushoDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 501-504 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Josué Barahona-Garrido Jesús K Yamamoto-Furusho New treatment options in the management of IBD – focus on colony stimulating factors |
| description |
Josué Barahona-Garrido, Jesús K Yamamoto-FurushoInflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Mexico City, MexicoAbstract: Inflammatory bowel disease (IBD) is characterized by inflammation of the gastrointestinal tract, typically with a relapsing and remitting clinical course. The intestinal inflammation in IBD is controlled by a complex interplay of innate and adaptive immune mechanisms. Innate immunity comprises a set of distinct elements, which includes circulating cells such as neutrophils, monocytes, and resident intestinal immune cells (dendritic and Paneth cells), as well as intestinal epithelium and cellular products, including antimicrobial peptides such as defensins and cathelicidins. Different components of innate immunity in IBD have been suggested to be defective or impaired. The human granulocyte-macrophage colony-stimulating factor (GM-CSF) and the human granulocyte colony-stimulating factor (G-CSF) have emerged as potential tools for the modulation of intestinal inflammation and repair. The greatest evidence supporting the use of colony-stimulating factors in intestinal inflammation comes from studies conducted in active Crohn’s disease (CD) patients treated with sargramostim and filgrastim, but evidence for its recommendation as treatment remains weak, as the majority of studies are open label, nonrandomized, and with a small number of patients.Keywords: inflammatory bowel disease, colony stimulating factors, sargramostim, filgrastim |
| format |
article |
| author |
Josué Barahona-Garrido Jesús K Yamamoto-Furusho |
| author_facet |
Josué Barahona-Garrido Jesús K Yamamoto-Furusho |
| author_sort |
Josué Barahona-Garrido |
| title |
New treatment options in the management of IBD – focus on colony stimulating factors |
| title_short |
New treatment options in the management of IBD – focus on colony stimulating factors |
| title_full |
New treatment options in the management of IBD – focus on colony stimulating factors |
| title_fullStr |
New treatment options in the management of IBD – focus on colony stimulating factors |
| title_full_unstemmed |
New treatment options in the management of IBD – focus on colony stimulating factors |
| title_sort |
new treatment options in the management of ibd – focus on colony stimulating factors |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/ae4eb40bcbdc485595374bc0943d78f7 |
| work_keys_str_mv |
AT josuampeacutebarahonagarrido newtreatmentoptionsinthemanagementofibdampndashfocusoncolonystimulatingfactors AT jesampuacuteskyamamotofurusho newtreatmentoptionsinthemanagementofibdampndashfocusoncolonystimulatingfactors |
| _version_ |
1718402916207820800 |